Explore the words cloud of the ReSOLUTE project. It provides you a very rough idea of what is the project "ReSOLUTE" about.
The following table provides information about the project.
Coordinator |
CEMM - FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
Organization address contact info |
Coordinator Country | Austria [AT] |
Project website | https://re-solute.eu/ |
Total cost | 23˙850˙000 € |
EC max contribution | 12˙000˙000 € (50%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2016-10-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2018 |
Duration (year-month-day) | from 2018-07-01 to 2023-06-30 |
Take a look of project's partnership.
The Research empowerment on solute carriers (ReSOLUTE) proposal aims at inducing a decisive acceleration in the intensity of SLC research worldwide while establishing solute carriers (SLCs) as a tractable target class. It is composed of a core consortium of seven academic/SME members (CeMM, Univ. of Oxford, Univ. of Manchester, AXXAM Spa, Univ. Leiden, Max-Planck Institut für medizinische Forschung, Univ. Wien) and six industrial partners (Pfizer Limited UK, Novartis Pharma AG, Boehringer-Ingelheim, Vifor Pharma Group, Sanofi Aventis Recherche et Développement, Bayer AG) with established and complementary expertise combining industry grade standards and systems level principle-driven analysis.
ReSOLUTE merges systematic and focused approaches: 1) the generation of reliable and validated ‘hardware’ such as cell lines, proteins, antibodies/high affinity binders and large ‘omics’ datasets, 2) a central deorphanisation process coupling genomic engineering to metabolomics and supported by genetic and proteomics studies, 3) a non-redundant process to test systematically the suitability of a certain SLC to a variety of assay formats, 4) a collection of interlinked networks that cover different expertise, datasets and functional connections among SLCs, integrated into large-scale data repositories and a dedicated knowledgebase. The ReSOLUTE strategy will be applied in parallel at the super-family level and, in a more in-depth manner, to a prioritized gene list elected to be potential drug targets. To implement this and achieve the expected goals, the consortium is supported by a large network of academic and industrial partners with specific knowledge of certain SLCs and tools, willing to be accessed at any time and provide specific expertise. Together with a strong dissemination and exploitation plan, we therefore expect that ReSOLUTE will transform the landscape of SLC research for years to come.
ReSOLUTE knowledgebase | Documents, reports | 2020-04-14 17:13:23 |
ReSOLUTE database | Websites, patent fillings, videos etc. | 2020-04-14 17:13:23 |
Data Management Plan 1 | Documents, reports | 2020-04-14 17:13:23 |
Data Mining | Documents, reports | 2020-04-14 17:13:23 |
Vector generation | Documents, reports | 2020-04-14 17:13:23 |
Take a look to the deliverables list in detail: detailed list of ReSOLUTE deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESOLUTE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESOLUTE" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More